Use of novel oral anticoagulants in patients with atrial fibrillation

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Atrial fibrillation (AF) is one of the most common arrhythmias, which results in disability and death in the patients. The mechanisms of systemic and local atrial activation of the coagulation system provoke the risk of stroke in the presence of even short AF episodes. Novel oral anticoagulants (NOACs), particularly rivaroxaban, have shown their efficacy in preventing stroke in patients with AF. The international ROCKET AF, XANTUS, PREFER, and RIVER studies have studied different aspects of anticoagulant therapy, on the basis of which, the use of rivaroroxaban has been approved for the prevention of ischemic stroke and systemic embolisms in patients with non-valvular AF; the efficacy and safety of the drug have been proven.

Full Text

Restricted Access

About the authors

V. Skvortsov

Volgograd State Medical University, Ministry of Health of Russia

Author for correspondence.
Email: vskvortsov1@ya.ru
ORCID iD: 0000-0002-2164-3537

Professor, MD

Russian Federation

B. Levitan

Astrakhan State Medical University, Ministry of Health of Russia

Email: vskvortsov1@ya.ru

Professor, MD

Russian Federation

O. Razvalyaeva

Volgograd State Medical University, Ministry of Health of Russia

Email: vskvortsov1@ya.ru
Russian Federation

References

  1. Максимов Р.С., Дмитриева Р.В., Деомидов Е.С. и др. Профилактика инсульта при фибрилляции предсердий у пожилых пациентов. Бюллетень медицинских Интернет-конференций. 2015; 5 (3): 176–8 [Maksimov R.S., Dmitrieva R.V., Deomidov E.S. et al. Profilaktika insul'ta pri fibrillyatsii predserdii u pozhilykh patsientov. Bulletin of Medical Internet Conferences. 2015; 5 (3): 176–8 (in Russ.)].
  2. Явелов И.С. Профилактика инсульта при неклапанной фибрилляции предсердий. Медицинский совет. 2017; 12: 154–60 [Yavelov I.S. Stroke prevention in non-valvular atrial fibrillation. what rocket af study results say. Medical Council. 2017; 12: 154–60 (in Russ.)]. doi: 10.21518/2079-701X-2017-12-154-160
  3. Kirchhof P., Benussi S., Zamorano J.L. et al. Рекомендации ESC по лечению пациентов с фибрилляцией предсердий, разработанные совместно с EACTS. Российский кардиологический журнал. 2017; 7 (147): 7–86 [Kirchhof P., Benussi S., Zamorano J.L. et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Russ J Cardiol. 2017; 7 (147): 7–86 (in Russ.)]. doi: 10.15829/1560-4071-2017-7-7-86
  4. Wynn G.J., Todd D.M., Webber M. et al. The European Heart Rhythm Association symptom classification for atrial fibrillation: validation and improvement through a simple modification. Europace. 2014; 16: 965–72. doi: 10.1093/europace/eut395
  5. Захарьян Е.А., Садовой В.И., Зекрияева С.Р., и др. Новые оральные антикоагулянты как эффективная и безопасная профилактика кардиоэмболического инсульта у пациентов с фибрилляцией предсердий. КТЖ. 2019; 4: 59–63 [Zaharyan E.A., Sadovoy V.I., Zekriyaeva S.R. et al. New oral anticoagulants as effective and safe prevention of cardioembolic stroke in atrial fibrillation patients. KTJ. 2019; 4: 59–63 (in Russ.)].
  6. Каногорский С.Г. Применение ривароксабана в реальной клинической практике: результаты проспективного наблюдательного исследования XANTUS у больных с фибрилляцией предсердий. Рациональная Фармакотерапия в Кардиологии. 2016; 12 (4): 443–9 [Kanorskii S.G. Application of rivaroxaban in clinical practice: results of a prospective observational study XANTUS in patients with atrial fibrillation. Ration Pharmacother Cardiol. 2016; 12 (4): 443–9 (in Russ.)]. doi: 10.20996/1819-6446-2016-12-4-443-449
  7. Куликов А.Ю., Проценко М.В., Сердечная Е.В. Фармакоэкономический анализ включения ривароксабана в текущие алгоритмы профилактики инсультов у пациентов с фибрилляцией предсердий. Кардиология. 2016; 56 (11): 71–7 [Kulikov A.Yu., Protsenko M.V., Serdechnaya E.V. Pharmacoeconomic analysis of the inclusion of rivaroxaban in the current algorithms prevention of the stroke in patients with atrial fibrillation. Cardiology. 2016; 56 (11): 71–7 (in Russ.)]. doi: 10.18565/cardio.2016.11.71-77
  8. Guimarães H.P., Lopes R.D., de Barros E. et al. RIVER Trial Investigators. Rivaroxaban in Patients with Atrial Fibrillation and a Bioprosthetic Mitral Valve. N Eng J Med. 2020; 383 (22): 2117–26. doi: 10.1056/NEJMoa2029603
  9. Остроумова О.Д., Воеводина Н.Ю., Гусева Т.Ф. и др. Профилактика инсульта у пациента с фибрилляцией предсердий и сопутствующими заболеваниями. Системные гипертензии. 2018; 15 (2): 55–9 [Ostroumova O.D., Voevodina N.Yu., Guseva T.F. et al. Stroke prevention in patients with atrial fibrillation and comorbidities. Systemic Hypertension. 2018; 15 (2): 55–9 (in Russ.)]. doi: 10.26442/2075-082X_2018.2.55-59
  10. Остроумова О.Д., Пиксин Г.Ф., Павлеева Е.Е. и др. Профилактика повторного инсульта у пациентов с фибрилляцией предсердий: фокус на эффективность и безопасность ривароксабана. Эффективная фармакотерапия. 2017; 33: 18–25 [Ostroumova O.D., Piksina G.F., Pavleyeva Ye.Ye. et al. Prevention of Recurrent Stroke in Patients with Atrial Fibrillation: Focus on Rivaroxaban Efficacy and Safety. Effektivnaya farmakoterapiya. 2017; 33: 18–25 (in Russ.)].
  11. Patti G., Lucerna M., Pecen L. et al. Thromboembolic Risk, Bleeding Outcomes and Effect of Different Antithrombotic Strategies in Very Elderly Patients with Atrial Fibrillation: A Sub-Analysis From the PREFER in AF (PRE vention F Thromboembolic Events- E uropean R egistry in A trial F ibrillation). J Am Heart Assoc. 2017; 6 (7): e005657. doi: 10.1161/JAHA.117.005657
  12. Martinez B.K., Sood N.A., Bunz T.J. et al. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients with Nonvalvular Atrial Fibrillation. J Am Heart Assoc. 2018; 7 (8): e008643. doi: 10.1161/JAHA.118.008643
  13. Russmann S., Niedrig D.F., Budmiger M. et al. Rivaroxaban postmarketing risk of liver injury. J Hepatol. 2014; 61 (2): 293–300. doi: 10.1016/j.jhep.2014.03.026
  14. Turpie A.G. New oral anticoagulants in atrial fibrillation. Eur Heart J. 2015; 29 (2): 155–65. doi: 10.1093/eurheartj/ehm575
  15. Brown D.G., Wilkerson E.C., Love W.E. A review of traditional and novel oral anticoagulant and antiplatelet therapy for dermatologists and dermatologic surgeons. J Am Acad Dermatol. 2015; 72 (3): 524–34. doi: 10.1016/j.jaad.2014.10.027

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies